| Oct 31 |
Evaxion Biotech ADS GAAP EPS of -$0.04, revenue of $3.01M
|
| Oct 31 |
Evaxion announces business update and third quarter 2024 financial results
|
| Oct 31 |
EVAX Exceeds Estimates and Confirms Partnership
|
| Oct 28 |
Evaxion to announce business update and third quarter 2024 financial results on October 31
|
| Oct 11 |
OTC Markets Hosts Virtual Investor Presentation with Christian Kanstrup, CEO of Evaxion Biotech, and Brad Sorensen, Senior Analyst at Zacks SCR
|
| Oct 9 |
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
|
| Oct 4 |
Evaxion Biotech Charts Future with Innovative Immune Therapies
|
| Oct 3 |
AI from EVAX Improves Trial Results
|
| Oct 3 |
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
|
| Sep 26 |
Evaxion stock jumps on expanded vaccine development pact with MSD
|
